Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

A. Burger, Robert; F. Brady, Mark; A. Bookman, Michael; F. Fleming, Gini; J. Monk, Bradley; Huang, Helen; S. Mannel, Robert; D. Homesley, Howard; M. Fowler, Jeffrey; E. Greer, Benjamin; Boente, Matthew; J. Birrer, Michael; X. Liang, Sharon

doi:10.1056/nejmoa1104390

Public

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

Published in New England Journal of Medicine • Dec 28, 2011

Authors:

Robert A. Burger

Mark F. Brady

Michael A. Bookman

Abstract

BACKGROUND: Vascular endothelial growth factor is a key promoter of angiogenesis and disease progression in epithelial ovarian cancer. Bevacizumab, a humanized anti-vascular endothelial growth factor monoclonal antibody, has shown single-agent activity in women with recurrent tumors. Thus, we aimed ...

Subject

Bevacizumab

Medicine

Ovarian cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!